HDAC6在消化系统原发恶性肿瘤中的研究进展  

Role of HDAC6 in primary digestive system malignancies

作　　者：张诗岚 李琛 刘德良[1] 谭玉勇[1] Shi-Lan Zhang;Chen Li;De-Liang Liu;Yu-Yong Tan(Department of Gastroenterology, the Second Xiangya Hospital of Central South University, Changsha 410011, Hu＇nan Province, China)

机构地区：[1]中南大学湘雅二医院消化内科,湖南省长沙市410011

出　　处：《世界华人消化杂志》2018年第14期827-833,共7页World Chinese Journal of Digestology

基　　金：国家临床重点专科项目;No.(2012)650~~

摘　　要：恶性肿瘤已成为继心血管疾病外全球第二大死亡原因.消化系统恶性肿瘤的发病率和死亡率在我国恶性肿瘤排名中均位居前列.肿瘤的发生发展是一个多因素参与、多阶段的过程,蛋白质的乙酰化和去乙酰化在肿瘤的发生发展中起着重要作用.蛋白质的去乙酰化由组蛋白去乙酰化酶(histone deacetylases,HDACs)调控.目前共发现18个HDACs,其中HDAC6是该家族中研究最广泛的一类亚型.HDAC6已被证实在多种肿瘤组织中呈高表达状态,并与患者临床病理特征密切相关,HDAC6选择性抑制剂可抑制多种肿瘤细胞生长.本文就HDAC6在消化系统原发恶性肿瘤中的作用及潜在应用价值进行作一述评.Cancer has become the second leading cause of death around the world following cardiovascular disease.The morbidity and mortality of digestive system malignancies rank among the top in malignant tumors. Cancer occurrence and development are a multi-factor and multi-stage process. Acetylation and deacetylation play an important role in the development of cancer. Deacetylation of proteins is regulated by histone deacetylases （HDACs）. A total of 18 human HDACs have been discovered, among which HDAC6 is the most widely studied. It has been demonstrated that HDAC6 is highly expressed in a variety of tumor tissues and associated with the clinicopathological characteristics of these tumors. What＇s more, HDAC6 selective inhibitors can inhibit the growth of many cancer cells. In the present review, we summarize the role of HDAC6 in primary digestive system malignancies.

关 键 词：蛋白质翻译后修饰 组蛋白去乙酰化酶6 消化系统恶性肿瘤 

分 类 号：R735[医药卫生—肿瘤]